Oxford, UK – 31 Jan 2022 – OxSonics® Therapeutics, a world leader in the development of ultrasound-based drug delivery systems for the treatment of cancer today announced the appointment of Gene Saragnese to the Board of Directors.
Gene Saragnese is a seasoned business strategist, technology thought leader, and medical imaging industry expert. He has held executive leadership positions as the Chief Executive Officer of Philips Imaging Systems, Vice President and Head of GE’s Molecular Imaging and CT business, and Chief Technology Officer and Vice President of Global Technology for GE Healthcare’s global business portfolio.
Allison Jeynes, Chair of OxSonics Board, said “I am delighted to welcome Gene to the board of Directors; he brings extensive strategic knowledge in medical imaging technology, and his 25+ years’ experience in leading product commercialisation and marketing activities on a global scale will be invaluable to the business as we establish ourselves as a clinical stage company and refine routes to commercialisation.”
Gene Saragnese commented “I believe that OxSonics’ technology can overcome a major challenge in treating a range of solid tumours. The SonoTran® platform has the potential to increase the efficacy of anti-cancer agents by increasing the dose and distribution in some of the toughest to treat cancers, and I look forward to working with the OxSonics team to get this product to market.”